迈威生物：9MW3811注射液临床试验申请获批

Core Viewpoint - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for its clinical trial application for 9MW3811 injection, aimed at treating pathological scars in a Phase II clinical trial [1] Group 1 - The company announced the approval of its clinical trial for 9MW3811 injection [1] - The indication for the clinical trial is pathological scars [1] - The approval is specifically for a Phase II clinical trial [1]